Need Help?
Contact Us

Rotational Atherectomy Systems

ROTABLATOR™ and ROTAPRO™ Rotational Atherectomy Systems

Features the front-cutting, stable rotation of a diamond-tipped burr recognized by physicians as an optimal device to ablate calcium in coronary arteries.

Key Resources

Peripheral ROTABLATOR System

Explore

Calcium Prevalence & Rotational Atherectomy

600+ Certified Operators in the US 600+ Certified Operators in the US

Certified operators in the US

25+ Years of Proven Clinical Safety and Efficacy 25+ Years of Proven Clinical Safety and Efficacy

Years of Proven Clinical Safety and Efficacy

1.1 million+ Procedures Performed Worldwide* 1.1 million+ Procedures Performed Worldwide*

Procedures Performed Worldwide*

* Based on Boston Scientific sales estimate.

Calcium Impacts Long-Term Outcomes

Calcium is a growing problem in the treatment of coronary artery disease. Angiographic evidence indicates a high presence of target lesion calcification in patients undergoing PCI.1

Rotablator - Calcium is a growing problem Rotablator - Calcium is a growing problem


Pooled analysis from the HORIZONS-AMI and ACUITY Trials suggests patients with moderate/severe calcium have a significantly higher chance of death, TLR, and MACE.1

HORIZONS-AMI & ACUITY Trials

1-Year Ischemic Outcomes

HORIZONS-AMI & ACUITY Trials - 1-Year Ischemic Outcomes HORIZONS-AMI & ACUITY Trials - 1-Year Ischemic Outcomes


2016 data from the ARRIVE Registry also shows that moderate/severe calcium is associated with higher risk of death, TVR, and MACE.2

ARRIVE Registry

1-Year Ischemic Outcomes

ARRIVE Registry - 1-Year Ischemic Outcomes ARRIVE Registry - 1-Year Ischemic Outcomes

Patients with calcium tend to be older with a higher prevalence of hypertension, kidney disease, previous CABG, and congestive heart failure.

Severe calcium significantly increases the chance of death, TLR, and MACE. Severe calcium significantly increases the chance of death, TLR, and MACE.

Data Supports Rotational Atherectomy

A 2015 large, multicenter registry evaluated the outcomes of patients undergoing rotational atherectomy (RA) in 9 major Australian hospitals over an 8-year period (16,410 non-RA PCIs, 167 RA PCIs).3

In the RA cohort:

  • Patients were more likely to be older with a higher prevalence of comorbidities
  • Patients were more likely to have complex type B2 and C lesions
  • 37% of patients had a previously failed PCI

These patients represented the most complex of the PCI population where no other interventional therapy was an option.

Study Findings: Rotational atherectomy was safe and effective in resistant lesions

In Hospital Clinical Outcome:

No significant difference in angiographic success, dissections, perforations, or no reflow

1-Year Clinical Outcome:

No significant difference in MACE or TLR*

 

1-year TLR (with DES) for the rotational atherectomy cohort was 2.9% 1-year TLR (with DES) for the rotational atherectomy cohort was 2.9%

When lesions treated with DES(excluding bare metal stents) were isolated, analysis of the multicenter registry revealed a TLR rate of 2.9%.

Summary:

  • Rotational atherectomy is an important tool for treating complex lesions, with low procedural complications and MACE rates.

  • Despite the significantly more difficult patient population, there were no significant differences in procedural complications.

  • Given the excellent results, an upfront rotational atherectomy strategy for treating calcium has the potential to:
    • Shorten procedure time
    • Reduce number of overall procedures
    • Reduce risks to patients

* “There was a small but significant increase in death at 12 months; however considering there was no difference in 30‑day mortality, this difference may be unrelated to RA itself and reflect the older demographic with higher prevalence of comorbidities in the cohort undergoing RA.”3

Reimbursement

The C-code used for this product is C1724, catheter, transluminal atherectomy, rotational. C-codes are used for hospital outpatient device reporting for Medicare and some private payers.

Note: Boston Scientific is not responsible for the correct use of codes on submitted claims; this information does not constitute reimbursement or legal advice.

 

Master the Complex - For Complete Revascularization Master the Complex - For Complete Revascularization
Top